Nitroglycerin is named as an intervention in 6 current clinical trials in our Taiwan, Egypt, China and Germany registers. 3 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is First Affiliated Hospital of Wannan Medical College (1). The most-studied condition is Acute Respiratory Failure (ARF).
Nitroglycerin was first approved in the US on 30 Sep 1981. It is approved in 2 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
| Condition (as registered) | Trials |
|---|---|
| Acute Respiratory Failure (ARF) | 1 |
| Hypertension | 1 |
| Pulmonary Perfusion Imbalance | 1 |
| Aortic Dissection (Subset) | 1 |
| Stable Coronary Artery Disease | 1 |
| Acute Kidney Injury (Nontraumatic) | 1 |
| Hypotension Drug-Induced | 1 |
| Pancreatitis | 1 |
| Bone Regeneration | 1 |
| Periodontal Bone Loss | 1 |
| Healing Fracture of Bone | 1 |
| COPD | 1 |
| COPD III/IV | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Taiwan | 2 | 2 |
| Clinical trials in Egypt | 2 | 1 |
| Clinical trials in China | 1 | 0 |
| Clinical trials in Germany | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
6 current trials in our Taiwan, Egypt, China and Germany registers name Nitroglycerin as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 3 of the 6 trials are recruiting: 2 with sites in Taiwan and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
First Affiliated Hospital of Wannan Medical College (1), Bayer (1), Kaohsiung Medical University Chung-Ho Memorial Hospital (1) and National Cheng-Kung University Hospital (1), among 6 lead sponsors in total. The number in brackets is how many trials each organisation leads.
The registers we track list 1 entry for Nitroglycerin: US FDA: resolved. Shortages are product- and country-specific; check with a pharmacist.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Nitroglycerin works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nitroglycerin works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nitroglycerin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.